Here are just a few editorial highlights from the DDNews Cancer Research News site and other online vehicles of DDNews magazine to get you acquainted with the website and show you the range of our coverage.
 

 
By Jeffrey Bouley, DDNews Chief Editor
Multiple Myeloma Research Foundation announces six new clinical trials in 2014, and Cellectar Biosciences announces IND for relapsed or refractory multiple myeloma drug
 
By Lloyd Dunlap, DDNews Managing Editor
With some tinkering, MIT chemists recruit anthrax to deliver anti-cancer drugs
 
Guest Commentary: Developing humanized cancer models for cost-effective and productive cancer drug discovery
By Dr. Jean-Pierre Wery, CrownBio
Oncology drug discovery faces one of the highest attrition rates for drug candidates in the development pipeline, largely due to efficacy issues. More relevant clinical models, ones that better reflect cancer heterogeneity and disease progression, could address this problem.
 
By Lloyd Dunlap, DDNews Managing Editor
FDA submission reinforces commitment to addressing significant unmet needs for patients with acute lymphoblastic leukemia, an aggressive cancer with limited treatment options
 
DDNews Cancer Research Exclusive: Turning an eye to TERT
By Kelsey Kaustinen, DDNews Senior Editor
As part of the TCGA initiative, researchers have discovered multiple cases of missing chromosomes in chromophobe renal cell carcinoma, as well as rearrangements in the promoter region of the TERT gene
 
 
 
 
 
GDBP gains license to monoclonal antibody for China
April 2012
SHARING OPTIONS:

GANSU, China—Privately held Apexigen and Gansu Duyiwei Biological Pharmaceutical (GDBP) have announced a collaboration that will provide GDBP with an exclusive license to develop and commercialize APX004 in China. APX004 is a humanized monoclonal antibody directed against VEGFR2 for the treatment of certain cancers and angiogenic diseases. Under the agreement, GDBP will be solely responsible for researching, developing and commercializing APX004 in China, while Apexigen will collaborate with GDBP to advance the development program and will retain all rights to the compound outside of China. Apexigen will receive an upfront payment, regulatory milestone payments and a royalty, though no specific financial details were disclosed. Zhiping Duan, CEO of GDBP, said the deal will become a developmental milestone for the company.

Back







CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2014 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.